BIAF - bioAffinity Technologies, Inc. Stock Analysis

Stock Taper

SCREENER COMPARE ANY 2 STOCKS

BIAF

BIOAFFINITY TECHNOLOGIES, INC.

NASDAQ

$4.87

▼ DOWN 3.75% (-0.19)

KEY STATISTICS

Market Cap$2.04 M

52w High$202.50

52w Low$4.87

Dividend Yield—

Frequency—

P/E-0.57

Volume30.05K

Shares Out.418.87K

COMPANY

LEADERSHIP

CHIEF EXECUTIVE

Maria Zannes

ABOUT

SECTOR

Healthcare

WENT PUBLIC

September 1, 2022

METHOD OF GOING PUBLIC

IPO

FULL TIME EMPLOYEES

UPCOMING EARNINGS

DateNov 18, 2026

DayWednesday

Rev. Est.$1.91M

NOV

WED

SPLIT RECORD

DATE	TYPE	RATIO
2026-08-24	Reverse	1:15
2025-09-19	Reverse	1:30

PRICE

$4.87 ▼ DOWN 3.75% (−$0.19)

OVERLAYS

About bioAffinity Technologies, Inc.

https://www.bioaffinitytech.com ↗

bioAffinity Technologies, Inc. is a Texas-based biotech company developing non-invasive diagnostic tests like CyPath lung for early cancer detection and targeted therapies at the cellular level.

INDUSTRY

Medical - Diagnostics & Research

A PRODUCT BIOAFFINITY TECHNOLOGIES, INC. IS KNOWN FOR

CyPath Lung

CyPath Lung is a non-invasive diagnostic test that uses flow cytometry and AI to detect early lung cancer in high-risk individuals from sputum samples, aiding clinical decisions after suspicious LDCT findings.